First Eagle Investment Management
CPXX

First Eagle Investment Management’s CELATOR PHARMACEUTICALS INC. COMMON STOCK CPXX Stock Holding History

First Eagle Investment Management’s Portfolio CPXX Stock Details CPXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-741,000
Closed -$8.17M – 372
2016
Q1 		$8.17M Buy
741,000
+128,400
+21% +$421K 0.02% 171
2015
Q4 		$1.08M Buy
+612,600
New +$1.05M ﹤0.01% 219

Other funds holding CPXX

CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

First Eagle Investment Management's CPXX Position: Q2 2016 in Review

First Eagle Investment Management sold out of CELATOR PHARMACEUTICALS INC. COMMON STOCK (CPXX) in Q2 2016, closing a stake of 741,000 shares — an estimated $8.17M sold.

First Eagle Investment Management first reported a position in CPXX in Q4 2015 and held it in 2 quarters. The position peaked at $8.17M in Q1 2016. 119 funds tracked by Wall St. Rank hold CPXX as of Q2 2016.

  • First Eagle Investment Management reported no remaining CELATOR PHARMACEUTICALS INC. COMMON STOCK position as of Q2 2016 after selling out during the quarter.
  • First Eagle Investment Management sold 741,000 CELATOR PHARMACEUTICALS INC. COMMON STOCK shares in Q2 2016, an estimated $8.17M.
  • First Eagle Investment Management first reported a position in CELATOR PHARMACEUTICALS INC. COMMON STOCK in Q4 2015 and held it in 2 quarters.
  • First Eagle Investment Management's CELATOR PHARMACEUTICALS INC. COMMON STOCK position peaked at $8.17M in Q1 2016.
  • 119 funds tracked by Wall St. Rank held CELATOR PHARMACEUTICALS INC. COMMON STOCK as of Q2 2016.

Based on First Eagle Investment Management's 13F filing for Q2 2016, filed 9 Aug 2016.